1.81
-0.09(-4.74%)
Currency In USD
| Previous Close | 1.9 |
| Open | 1.89 |
| Day High | 1.94 |
| Day Low | 1.79 |
| 52-Week High | 2.54 |
| 52-Week Low | 0.62 |
| Volume | 288,050 |
| Average Volume | 510,634 |
| Market Cap | 228.61M |
| PE | -3.62 |
| EPS | -0.5 |
| Moving Average 50 Days | 1.62 |
| Moving Average 200 Days | 1 |
| Change | -0.09 |
If you invested $1000 in Nautilus Biotechnology, Inc. (NAUT) since IPO date, it would be worth $173.37 as of December 17, 2025 at a share price of $1.81. Whereas If you bought $1000 worth of Nautilus Biotechnology, Inc. (NAUT) shares 3 years ago, it would be worth $1,145.57 as of December 17, 2025 at a share price of $1.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
GlobeNewswire Inc.
Nov 03, 2025 1:00 PM GMT
• Buck Institute’s deployment of Nautilus’ instrument generates tau proteoform data, providing external validation of the company’s next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites an
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 202
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2025 bef